115 related articles for article (PubMed ID: 21207414)
21. Morphologic and Molecular Characteristics of De Novo AML With
Hidalgo-López JE; Kanagal-Shamanna R; Medeiros LJ; Estrov Z; Yin CC; Verstovsek S; Konoplev S; Jorgensen JL; Mohammad MM; Miranda RN; Zhao C; Lee J; Zuo Z; Bueso-Ramos CE
J Natl Compr Canc Netw; 2017 Jun; 15(6):790-796. PubMed ID: 28596259
[No Abstract] [Full Text] [Related]
22. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express Aurora kinase A.
Yang J; Ikezoe T; Nishioka C; Nobumoto A; Udaka K; Yokoyama A
Int J Cancer; 2013 Dec; 133(11):2706-19. PubMed ID: 23686525
[TBL] [Abstract][Full Text] [Related]
23. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
[TBL] [Abstract][Full Text] [Related]
24. CD45
Heo SK; Noh EK; Ju LJ; Sung JY; Jeong YK; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Apr; 20(1):285. PubMed ID: 32252668
[TBL] [Abstract][Full Text] [Related]
25. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.
Kaufmann SH; Karp JE; Svingen PA; Krajewski S; Burke PJ; Gore SD; Reed JC
Blood; 1998 Feb; 91(3):991-1000. PubMed ID: 9446661
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias.
Illmer T; Schaich M; Ehninger G; Thiede C;
Haematologica; 2007 Jan; 92(1):137-8. PubMed ID: 17229652
[TBL] [Abstract][Full Text] [Related]
27. Induction failure in de novo acute myelogenous leukemia is associated with expression of high levels of CD34 antigen by the leukemic blasts.
Dalal BI; Wu V; Barnett MJ; Horsman DE; Spinelli JJ; Naiman SC; Shepherd JD; Nantel SH; Reece DE; Sutherland HJ; Klingemann HG; Phillips GL
Leuk Lymphoma; 1997 Jul; 26(3-4):299-306. PubMed ID: 9322892
[TBL] [Abstract][Full Text] [Related]
28. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
[TBL] [Abstract][Full Text] [Related]
29. Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.
Wu QY; Ma MM; Zhang S; Liu Y; Cao J; Yan ZL; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2019 Mar; 124():1123-1131. PubMed ID: 30521925
[TBL] [Abstract][Full Text] [Related]
30. JAK2 inhibition in JAK2
Dahlström J; Xia C; Xing X; Yuan X; Björkholm M; Xu D
Biochem Biophys Res Commun; 2020 Jun; 527(2):425-431. PubMed ID: 32334833
[TBL] [Abstract][Full Text] [Related]
31. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
32. Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML.
de Jonge HJ; Woolthuis CM; Vos AZ; Mulder A; van den Berg E; Kluin PM; van der Weide K; de Bont ES; Huls G; Vellenga E; Schuringa JJ
Leukemia; 2011 Dec; 25(12):1825-33. PubMed ID: 21760593
[TBL] [Abstract][Full Text] [Related]
33. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia.
Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y
Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862
[TBL] [Abstract][Full Text] [Related]
34. Low CLL-1 Expression Is a Novel Adverse Predictor in 123 Patients with De Novo CD34
Wang YY; Chen WL; Weng XQ; Sheng Y; Wu J; Hao J; Liu ZY; Zhu YM; Chen B; Xiong SM; Chen Y; Chen QS; Sun HP; Li JM; Wang J
Stem Cells Dev; 2017 Oct; 26(20):1460-1467. PubMed ID: 28810819
[TBL] [Abstract][Full Text] [Related]
35. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
Quintás-Cardama A; Manshouri T; Estrov Z; Harris D; Zhang Y; Gaikwad A; Kantarjian HM; Verstovsek S
Invest New Drugs; 2011 Oct; 29(5):818-26. PubMed ID: 20372971
[TBL] [Abstract][Full Text] [Related]
36. BH3 mimetic ABT-737 induces apoptosis in CD34
Rao J; Li F; Zhang RY; Zhou HH; Chen GA
Asia Pac J Clin Oncol; 2017 Apr; 13(2):e144-e152. PubMed ID: 26552712
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
38. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
[TBL] [Abstract][Full Text] [Related]
39. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Kornblau SM; Vu HT; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May WS
Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
[TBL] [Abstract][Full Text] [Related]
40. Potential CD34 signaling through phosphorylated-BAD in chemotherapy-resistant acute myeloid leukemia.
Yiau SK; Lee C; Mohd Tohit ER; Chang KM; Abdullah M
J Recept Signal Transduct Res; 2019 Jun; 39(3):276-282. PubMed ID: 31509041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]